{"id":21647,"date":"2023-08-11T08:02:32","date_gmt":"2023-08-11T12:02:32","guid":{"rendered":"https:\/\/medicarereport.org\/?p=21647"},"modified":"2023-08-11T08:02:33","modified_gmt":"2023-08-11T12:02:33","slug":"new-alzheimers-drug-raises-hopes-along-with-questions","status":"publish","type":"post","link":"https:\/\/medicarereport.org\/?p=21647","title":{"rendered":"New Alzheimer\u2019s Drug Raises Hopes \u2014 Along With Questions"},"content":{"rendered":"\n<p>(By Judith Graham for KFF Health News)<\/p>\n\n\n\n<p>The FDA has approved Leqembi, the first disease-modifying treatment for early-stage Alzheimer\u2019s and a precursor condition, mild cognitive impairment. Medicare has said it will pay for the therapy. Medical centers across the country are scrambling to finalize policies and procedures for providing the medication to patients, possibly by summer\u2019s end or early autumn.<\/p>\n\n\n\n<p>It\u2019s a fraught moment, with hope running high for families and other promising therapies such as donanemab on the horizon. Still, medical providers are cautious. \u201cThis is an important first step in developing treatments for complex neurodegenerative diseases, but it\u2019s just a first step,\u201d said Ronald Petersen, director of the Mayo Clinic\u2019s Alzheimer\u2019s Disease Research Center in Rochester, Minnesota.  Continue reading <a href=\"https:\/\/kffhealthnews.org\/news\/article\/leqembi-new-alzheimers-drug-raises-hopes-questions\/\" data-type=\"link\" data-id=\"https:\/\/kffhealthnews.org\/news\/article\/leqembi-new-alzheimers-drug-raises-hopes-questions\/\">here&#8230;<\/a><\/p>\n\n\n\n<p class=\"has-small-font-size\">KFF Health News is a national newsroom that produces in-depth journalism about health issues and is one of the core operating programs at KFF \u2014 the independent source for health policy research, polling, and journalism<\/p>\n\n\n\n<p><img loading=\"lazy\" decoding=\"async\" width=\"175\" height=\"20\" class=\"wp-image-21118\" style=\"width: 175px;\" src=\"https:\/\/medicarereport.org\/wp-content\/uploads\/2023\/04\/image.png\" alt=\"\" srcset=\"https:\/\/medicarereport.org\/wp-content\/uploads\/2023\/04\/image.png 500w, https:\/\/medicarereport.org\/wp-content\/uploads\/2023\/04\/image-300x34.png 300w\" sizes=\"auto, (max-width: 175px) 100vw, 175px\" \/><\/p>\n\n\n\n<p class=\"has-small-font-size\"><strong>Notice:<\/strong> The link provided above connects readers to the full content of the posted article. The URL (internet address) for this link is valid on the posted date; medicarereport.org cannot guarantee the duration of the link\u2019s validity. Also, the opinions expressed in these postings are the viewpoints of the original source and are not explicitly endorsed by AMAC, Inc.; the AMAC Foundation, Inc.; or medicarereport.org<\/p>\n","protected":false},"excerpt":{"rendered":"<p>(By Judith Graham for KFF Health News) The FDA has approved Leqembi, the first disease-modifying treatment for early-stage Alzheimer\u2019s and<\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[18,26,31,6],"tags":[116,252,599,76,769,61],"class_list":["post-21647","post","type-post","status-publish","format-standard","hentry","category-aging","category-alzheimersdementia","category-fda","category-medicare-general","tag-alzheimers-disease","tag-alzheimers-treatment","tag-donanemab","tag-fda","tag-leqembi","tag-medicare"],"_links":{"self":[{"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/posts\/21647","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/medicarereport.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=21647"}],"version-history":[{"count":1,"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/posts\/21647\/revisions"}],"predecessor-version":[{"id":21648,"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/posts\/21647\/revisions\/21648"}],"wp:attachment":[{"href":"https:\/\/medicarereport.org\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=21647"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/medicarereport.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=21647"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/medicarereport.org\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=21647"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}